All Releases
 |
PPD Scientist Recognized for Contributions in Clinical Research
Mar 5, 2012
|
8.2 KB |
| |
WILMINGTON, N.C. (December 12, 2007) - PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Philip Mathew, M.D., as director of strategic development, to lead the company's Phase II-IV operations and expansion in India.
Dr. Mathew will provide strategic leadership for PPD's drug development business on the Indian subcontine...
|
|
PPD Recognized for Expertise in Clinical Research
Feb 20, 2012
|
14.2 KB |
| |
WILMINGTON, N.C., (February 20, 2012) - Demonstrating its expertise in clinical research, Pharmaceutical Product Development, LLC (PPD) today announced that PharmaTimes magazine has named a team of PPD researchers the 2012 Clinical Team of the Year.
The honor...
|
|
PPD Recognized for Outstanding Employee Training and Development
Feb 14, 2012
|
16.2 KB |
| |
WILMINGTON, N.C., (February 14, 2012) - Highlighting its commitment to employees and clients, Pharmaceutical Product Development, LLC (PPD) today announced that Training magazine has named the global ...
|
|
Scottish Government and PPD Announce Strategic Alliance to Advance Clinical Research in Scotland
Feb 9, 2012
|
10.5 KB |
| |
EDINBURGH, SCOTLAND, and WILMINGTON, N.C., (February 9, 2012) - The Scottish government and Pharmaceutical Product Development, LLC (PPD) today announced a unique alliance designed to increase the amount of clinical research conducted in Scotland, accelerate the development of new medical therapies and enhance health care treatment option...
|
|
Dow AgroSciences, BioDuro to Collaborate on Crop Protection Discovery Research
Feb 7, 2012
|
13.0 KB |
| |
INDIANAPOLIS and WILMINGTON, N.C. - (February 7, 2012) - Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and BioDuro, a PPD® Company, announced today a three-year, multi-program discovery research agreement to generate novel molecules for synthesizing and testing fungicides, insecticides...
|
|
PPD and VirtualScopics Expand Strategic Alliance for Medical Imaging Services
Jan 26, 2012
|
13.6 KB |
| |
WILMINGTON, N.C., and ROCHESTER, N.Y., (January 26, 2012) - Pharmaceutical Product Development, Inc. and VirtualScopics, Inc. (Nasdaq: VSCP) today announced they have expanded their successful one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nerv...
|
|
The Carlyle Group and Hellman & Friedman Complete Acquisition of PPD
Dec 5, 2011
|
12.8 KB |
| |
WILMINGTON, N.C., (December 5, 2011) - Pharmaceutical Product Development, Inc. today announced the completion of its acquisition by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion.
As previously announced, the transaction was approved by PPD ...
|
|
PPD Announces Shareholder Approval of Merger with Affiliates of The Carlyle Group and Hellman & Friedman
Nov 30, 2011
|
9.5 KB |
| |
WILMINGTON, N.C., (November 30, 2011) - Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced that its shareholders have voted to approve the adoption of the agreement and plan of merger, dated October 2, 2011, providing for the merger of the company with an entity controlled by affiliates of The Carlyle Group and affili...
|
|
PPD Named Best Contract Research Organization and Honored for Best Technological Development in Clinical Trials by Scrip
Nov 4, 2011
|
15.2 KB |
| |
WILMINGTON, N.C., (November 4, 2011) - Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced it has been named the best contract research organization by Scrip Intelligence, which also has honored PPD for deploying the best technological development in clinical trials.
Scrip presented both awards to...
|
|
PPD Declares Fourth Quarter Dividend
Nov 2, 2011
|
9.6 KB |
| |
WILMINGTON, N.C. (November 2, 2011) - Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced that its board of directors declared a cash dividend for the fourth quarter of 2011 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share. The record date for the fourth quarter dividend is ...
|
|
PPD Announces End of "Go-Shop" Period and Early Termination of Hart-Scott-Rodino Waiting Period
Nov 2, 2011
|
12.1 KB |
| |
WILMINGTON, N.C. (November 2, 2011) - Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced the expiration of the 30-day "go-shop" period pursuant to the terms of the previously announced definitive merger agreement, entered into on October 2, 2011, between PPD and affiliates of The Carlyle Group and affiliates of Hellma...
|
|
PPD Announces 2011 PPD Beach2Battleship Triathlon Heroes
Oct 13, 2011
|
15.6 KB |
| |
WILMINGTON, N.C., (October 13, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced the 2011 PPD Heroes team, featuring cancer survivors and medical specialists competing as triathletes in the PPD Beach2Battleship Triathlon on Oct. 29. The PPD Heroes are helping raise public awareness about the value of participating in clinical trials in the...
|
|
PPD to be Acquired by The Carlyle Group and Hellman & Friedman
Oct 3, 2011
|
17.3 KB |
| |
PPD shareholders to receive $33.25 per share in cash
Transaction value is approximately $3.9 billion
PPD to become a privately held company
WILMINGTON, N.C. (October 3, 2011) - Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced that it has entered into a de...
|
|
PPD Expands Clinical Microbiology Laboratory Services Globally
Sep 21, 2011
|
11.8 KB |
| |
WILMINGTON, N.C., (September 21, 2011) -- PPD, Inc. (Nasdaq: PPDI) today announced it has expanded its clinical microbiology laboratory at its global centra...
|
|
PPD Appoints Raymond Hill as Chief Executive Officer and Member of the Board of Directors
Sep 19, 2011
|
10.8 KB |
| |
WILMINGTON, N.C. (September 19, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors has named Raymond H. Hill as PPD's new chief executive officer and elected him to the board of directors, both effective September 16.
Mr. Hill comes to PPD after eight years with IMS Health, Inc., a provider of data, marke...
|
|
PPD Named to InformationWeek 500 List of U.S. Business Technology Innovators
Sep 14, 2011
|
11.6 KB |
| |
WILMINGTON, N.C. (September 14, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has been named to the 2011 InformationWeek 500, an annual list of the most innovative users of business technology in the United States. The award recognizes PPD's leadership in technology investments, strategies and practices that contribute to effective ...
|
|
PPD Declares Third Quarter 2011 Dividend
Aug 24, 2011
|
9.6 KB |
| |
WILMINGTON, N.C., (August 24, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors has declared a cash dividend for the third quarter of 2011 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share. The record date for the third quarter dividend is September 15, 2011, and the...
|
|
PPD Names Jasmine (Jisong) Cui Chief Scientific Officer of BioDuro
Aug 16, 2011
|
13.4 KB |
| |
WILMINGTON, N.C., (August 16, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has appointed Jasmine (Jisong) Cui, Ph.D., as chief scientific officer of BioDuro, A PPD® Company. Dr. Cui will provide scientific leadership to BioDuro's integrated drug discovery services acr...
|
|
PPD's Dr. Henrietta Ukwu Honored as Influential Leader for Pioneering Work in Global Regulatory Affairs
Aug 1, 2011
|
13.6 KB |
| |
WILMINGTON, N.C., (August 1, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that Dr. Henrietta Ukwu, senior vice president for global regulatory affairs, has been named to the 2011 PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
The honor from PharmaVOICE magazine recognizes Dr. Ukw...
|
|
PPD Reports Second Quarter 2011 Financial Results
Jul 26, 2011
|
120.5 KB |
| |
Highlights:
Gross authorizations of $753 million
Net book-to-bill ratio of 1.29
Clinical Development Services segment net revenue growth of 14.1% over Q2 2010
Sequential Laboratory Services segment operating margin expansion
Diluted EPS of $0.41
...
|
|
|
